Small cell carcinoma
disease diseaseOn this page
Also known as oat cell canceroat cell carcinomasmall cell cancersmall cell car. (extrapulmonary)small cell carcinoma (extrapulmonary)small cell NECsmall cell neuroendocrine carcinoma
Summary
Small cell carcinoma (MONDO:0000402) is a cancer (an umbrella term covering 18 Mondo subtypes) with 6 GWAS associations across 1 studies and 18 clinical trials. Top therapeutic interventions include cisplatin, abiraterone, and apalutamide. A subtype of neuroendocrine carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 18 Mondo subtypes
- GWAS associations: 6
- Clinical trials: 18
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | small cell carcinoma |
| Mondo ID | MONDO:0000402 |
| EFO | EFO:0008524 |
| MeSH | D018288 |
| DOID | DOID:0050685 |
| NCIT | C3915, C4099 |
| SNOMED CT | 11010461000119101 |
| UMLS | C0334239 |
| MedGen | 90748 |
| GARD | 0022765 |
| Is cancer (heuristic) | yes |
Also known as: oat cell cancer · oat cell carcinoma · small cell cancer · small cell car. (extrapulmonary) · small cell carcinoma · small cell carcinoma (extrapulmonary) · small cell NEC · small cell neuroendocrine carcinoma
Data availability: 6 GWAS associations (1 study).
Disease family
This is a subtype of neuroendocrine carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › neuroendocrine carcinoma › small cell carcinoma
Related subtypes (11): anal canal neuroendocrine neoplasm, large cell neuroendocrine carcinoma, pancreatic endocrine carcinoma, combined lung carcinoma, malignant adrenal gland pheochromocytoma, liver neuroendocrine carcinoma, medullary thyroid gland carcinoma, goblet cell carcinoma, cutaneous neuroendocrine carcinoma, thymic neuroendocrine carcinoma, vulvar neuroendocrine carcinoma
Subtypes (18): extrahepatic bile duct small cell adenocarcinoma, ovarian small cell carcinoma, colon small cell neuroendocrine carcinoma, urinary bladder small cell neuroendocrine carcinoma, esophageal small cell neuroendocrine carcinoma, ampulla of vater small cell neuroendocrine carcinoma, Bartholin gland small cell carcinoma, thymus small cell carcinoma, cervical small cell carcinoma, endometrial small cell carcinoma, gallbladder small cell neuroendocrine carcinoma, gastric small cell neuroendocrine carcinoma, laryngeal small cell carcinoma, pancreatic small cell neuroendocrine carcinoma, prostate small cell carcinoma, salivary gland small cell carcinoma, ureter small cell carcinoma, small cell lung carcinoma
Genetics & variants
GWAS landscape
6 GWAS associations across 1 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr15:78618839 | 2e-09 | C | 0.28 | |
| chr5:132873727 | 6e-07 | T | 8.74 | |
| chr9:137213846 | 2e-06 | T | 5.49 | |
| chr12:55703100 | 2e-06 | A | 0.22 | |
| chr14:73592128 | 4e-06 | T | 0.12 | |
| chr19:18857406 | 4e-06 | T | 17.11 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90296663 | Shen S | 2023 | 282 | 334,643 | A Large-Scale Exome-Wide Association Study Identifies Novel Germline Mutations in Lung Cancer. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 6 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 2 |
| low_freq (0.01-0.05) | 1 |
| rare (<0.01) | 3 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| unknown | 6 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr15:78618839 | 0.392 | 2e-09 | Tier 4: intronic/intergenic | |||||
| chr5:132873727 | 0 | 6e-07 | Tier 4: intronic/intergenic | |||||
| chr9:137213846 | 0 | 2e-06 | Tier 4: intronic/intergenic | |||||
| chr12:55703100 | 0.027 | 2e-06 | Tier 4: intronic/intergenic | |||||
| chr14:73592128 | 0.371 | 4e-06 | Tier 4: intronic/intergenic | |||||
| chr19:18857406 | 0 | 4e-06 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Status |
|---|---|
| Etoposide | Approved (phase 4) |
2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Ipilimumab | Phase 2 |
| Nivolumab | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 18.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE1/PHASE2 | 5 |
| PHASE1 | 3 |
| Not specified | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02721732 | PHASE2 | ACTIVE_NOT_RECRUITING | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic |
| NCT03333616 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors |
| NCT04079712 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors |
| NCT04802174 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers |
| NCT07206563 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Penfluridol for Relapsed/Refractory Small Cell Cancers |
| NCT00907569 | PHASE2 | COMPLETED | Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer |
| NCT01642251 | PHASE1/PHASE2 | COMPLETED | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer |
| NCT02489903 | PHASE2 | COMPLETED | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) |
| NCT03910660 | PHASE1/PHASE2 | COMPLETED | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. |
| NCT04926181 | PHASE2 | TERMINATED | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer |
| NCT05551117 | PHASE2 | TERMINATED | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors |
| NCT07328490 | PHASE1/PHASE2 | WITHDRAWN | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer |
| NCT00466232 | PHASE1 | COMPLETED | Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer |
| NCT00469222 | PHASE1 | COMPLETED | Hypofractionated Radiotherapy for Small Cell Lung Cancer |
| NCT02881125 | PHASE1 | COMPLETED | Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma |
| NCT05621837 | Not specified | RECRUITING | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy |
| NCT00469066 | Not specified | COMPLETED | Cone Beam CT Scanning in Lung and Bladder Cancer. |
| NCT04028479 | Not specified | COMPLETED | The Registry of Oncology Outcomes Associated With Testing and Treatment |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 2 |
| ABIRATERONE | 4 | 1 |
| APALUTAMIDE | 4 | 1 |
| CABOZANTINIB | 4 | 1 |
| LURBINECTEDIN | 4 | 1 |
| NORTRIPTYLINE HYDROCHLORIDE | 4 | 1 |
| SACITUZUMAB GOVITECAN | 4 | 1 |
| TARLATAMAB | 4 | 1 |
| VELIPARIB | 3 | 2 |
| CETRELIMAB | 3 | 1 |
| NIBROZETONE | 3 | 1 |
| BERZOSERTIB | 2 | 1 |
| VOBRAMITAMAB DUOCARMAZINE | 2 | 1 |
| CHEMBL5397028 | 0 | 1 |
| CHEMBL4878843 | 0 | 1 |
| CHEMBL3780847 | 0 | 1 |
| CHEMBL4783522 | 0 | 1 |